Metis TechBio Co., Ltd. announced the full exercise of its over-allotment option, issuing an additional 30.18 million H shares—equivalent to 15% of the initial global offering—at HK$10.50 per share. The move brings in approximately HK$304.20 million in net proceeds after underwriting fees and expenses.

Following the allotment, total issued shares rise to 1.18 billion. The post-exercise capital structure shifts to: • Unlisted shares: 99.59 million, or 8.42% of total • H shares converted from unlisted shares: 851.70 million, or 72.01% • H shares from the global offering (including over-allotment): 231.41 million, or 19.57%

Hong Kong Stock Exchange approval for the new shares is in place, and trading is scheduled to begin on 10 June 2026.

The stabilization period associated with the IPO ends on 7 June 2026. During this window, CLSA Limited over-allocated 30.18 million shares and subsequently covered the position entirely through the exercised option; no on-market purchases or sales were conducted for price stabilization.

After the additional issuance, Metis TechBio maintains compliance with listing rules requiring a minimum 15% public float.